Chemicals & Advanced Materials Global On demand · 24-48h

Global Urolithin B Market Strategic Research Report

Global Urolithin B Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Urolithin B Market
$27.012025
6.2%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Purity: >98%, Purity: >99%, Others

By Application: Food Additives, Cosmetics, Drugs and Supplements, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Suzhou Myland Pharm & Nutrition Inc., Carlo Sessa SpA, Shandong Longilat Biotechnology Co., Ltd, Cofttek, BINBO BIOLOGICAL CO., LTD, Xi'an Jincuifang Plant Technology Development Co., Ltd., Nanjing Bencao Yikang Biotechnology Co., Ltd., Hubei Wanzhi Chemical Pharmaceutical Co., Ltd., Zhejiang Hengtengfu Pharmaceutical Co., Ltd., Xi'an Tianguangyuan Biotechnology Co., Ltd., Wuhan Dongkangyuan Technology Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 124 pages
Market size 2025
$27.01
Million USD
Forecast CAGR
6.2%
2025-2032
Forecast 2032
$41.2
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Urolithin B market size is predicted to grow from US$ 27.01 million in 2025 to US$ 40.9 million in 2032; it is expected to grow at a CAGR of 6.2% from 2026 to 2032.

In 2024, global Urolithin B production reached approximately 63 tons, with an average global market price of around US$ 416,000 per ton. In 2024, the global's total production capacity of Urolithin B reached 95 tons.The industry average gross profit margin of this product reached 32%.

Urolithin B is a natural metabolite produced by gut microbiota, derived from ellagitannins found in foods such as pomegranates and walnuts. Due to its potential in antioxidation, anti-inflammation, and metabolic regulation, it is attracting attention from the research community and the market. The upstream core is the raw material production and technological research and development of urolithin B. Companies mainly extract ellagitannins from natural plants (such as pomegranate peel and nut shells) or produce urolithin B monomers on a large scale through chemical synthesis and microbial fermentation. This segment has high technological barriers and is concentrated in a few raw material companies with biotransformation or synthesis capabilities. The output is high-purity raw material powder, and its price is directly related to purity (usually 90%-99%), production capacity, and technological costs, forming the basic supply end of the industry chain. Midstream companies transform upstream raw materials into end products, addressing the problems of poor water solubility and low bioavailability of urolithin B (often using cyclodextrin inclusion complexation and nanoemulsification technologies). Manufacturers of health products, cosmetics, and functional foods then combine the raw materials with other ingredients to produce specific products such as capsules, tablets, and skincare products. Downstream currently focuses on dietary supplements (anti-aging, mitochondrial health) and high-end skincare products (antioxidant, anti-inflammatory), while its presence in the pharmaceutical field is still in the clinical research stage.

In recent years, research on the mechanism by which urolithin B can efficiently cross the blood-brain barrier to exert its neuroprotective effects has provided crucial scientific support for its application in high-value areas such as anti-aging and prevention of neurodegenerative diseases (e.g., Alzheimer's disease). This upgrade in understanding from "traditional antioxidant" to "precise cellular metabolic regulation" is its core competitive advantage, distinguishing it from ordinary health supplements.

The global aging population and the shift in health concepts among consumers (especially high-net-worth individuals) from "disease treatment" to "proactive prevention and function enhancement" perfectly align with the huge market demand for "healthy aging" given urolithin B's potential in promoting mitochondrial health and reducing chronic inflammation (one of the main culprits of aging).

Currently, its applications are rapidly expanding from dietary supplements to high-end functional skincare products (focusing on anti-aging and repair) and specific medical nutritional products. The gradually clarifying regulatory environment (e.g., some countries managing it as a new food ingredient) has also created conditions for the compliant market launch of its products.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Urolithin B market?

What factors are driving Urolithin B market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Urolithin B market opportunities vary by end market size?

How does Urolithin B break out by Type, by Application?

This report presents a comprehensive overview of the global Urolithin B market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Purity: >98%
  • Purity: >99%
  • Others

Segment by Production Source

  • Natural Extraction
  • Chemical Synthesis

Segment by Product Specification

  • Industrial Grade
  • Food Grade

Segment by Existence Form

  • Powder
  • Solution

Segment by Application

  • Food Additives
  • Cosmetics
  • Drugs and Supplements
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Urolithin B market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Food Additives, Cosmetics, Drugs and Supplements evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Urolithin B Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.2%
Regional growth momentum
Market share by segment
Key metrics
Base value
$27.01
2025
Forecast
$41.2
2032
CAGR
6.2%
2025–2032
Regiones
5
global
Key companies
Suzhou Myland Pharm & Nutrition Inc.Carlo Sessa SpAShandong Longilat Biotechnology Co., LtdCofttekBINBO BIOLOGICAL CO., LTDXi'an Jincuifang Plant Technology Development Co., Ltd.Nanjing Bencao Yikang Biotechnology Co., Ltd.Hubei Wanzhi Chemical Pharmaceutical Co., Ltd.
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Purity: >98%Purity: >99%Others
By Application
Food AdditivesCosmeticsDrugs and SupplementsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Purity: >98%
  • 3.1.3 Purity: >99%
  • 3.1.4 Others
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Food Additives
  • 4.1.3 Cosmetics
  • 4.1.4 Drugs and Supplements
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Suzhou Myland Pharm & Nutrition Inc.
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Carlo Sessa SpA
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Shandong Longilat Biotechnology Co., Ltd
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Cofttek
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 BINBO BIOLOGICAL CO.,LTD
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Xi'an Jincuifang Plant Technology Development Co., Ltd.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Nanjing Bencao Yikang Biotechnology Co., Ltd.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Hubei Wanzhi Chemical Pharmaceutical Co., Ltd.
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Zhejiang Hengtengfu Pharmaceutical Co., Ltd.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Xi'an Tianguangyuan Biotechnology Co., Ltd.
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Wuhan Dongkangyuan Technology Co., Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Urolithin B market?
The global Urolithin B market is estimated at US$ 27.01 million in 2025 (base year) and is projected to reach US$ 40.9 million by 2032.
How fast is the Urolithin B market expected to grow?
The market is expected to grow at a CAGR of 6.2% from 2026 to 2032, expanding from US$ 27.01 million in 2025 to US$ 40.9 million in 2032, roughly 1.5 times its base-year value.
What does the Urolithin B market cover?
In 2024, global Urolithin B production reached approximately 63 tons, with an average global market price of around US$ 416,000 per ton. In 2024, the global's total production capacity of Urolithin B reached 95 tons.The industry average gross profit margin of this product reached 32%.
What are the main segments of the Urolithin B market by type?
By type, the market is segmented into Purity: >98%, Purity: >99% and Others.
Which applications drive demand in the Urolithin B market?
Key applications covered include Food Additives, Cosmetics, Drugs and Supplements and Others.
Who are the key players in the Urolithin B market?
Key players profiled include Suzhou Myland Pharm & Nutrition Inc., Carlo Sessa SpA, Shandong Longilat Biotechnology Co., Cofttek, BINBO BIOLOGICAL CO.,LTD, Xi'an Jincuifang Plant Technology Development Co., Nanjing Bencao Yikang Biotechnology Co. and Hubei Wanzhi Chemical Pharmaceutical Co., among 11 companies covered in total.
Which regions and countries are covered for Urolithin B?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Urolithin B market?
What factors are driving Urolithin B market growth, globally and by region?
What challenges does the Urolithin B market face?
This segment has high technological barriers and is concentrated in a few raw material companies with biotransformation or synthesis capabilities.
Who should buy the Urolithin B market report?
The report is intended for manufacturers and solution providers, distributors and end users in Food Additives, Cosmetics and Drugs and Supplements, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Urolithin B market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.